EMA launches consultation to streamline nonclinical development for life-threatening diseases
read at raps ↗RegulatoryNeutral
EMA announced a public consultation on proposals to accelerate the nonclinical phase of drug development for diseases that are severely debilitating or life‑threatening.
The agency aims to reduce unnecessary animal studies and shorten timelines while maintaining safety standards. Stakeholders are invited to comment on the draft guidance.
The consultation is part of EMA’s broader effort to improve access to innovative therapies across Europe.
source
This writeup was produced by pharmadog from original reporting by raps.
Original headline: “Euro Roundup: EMA seeks feedback on streamlining drug development for life-threatening diseases”
read at raps ↗
comments(0)
5-min edit window · permanent after that